

# SCIENCE TO ADVANCE LIVER HEALTH

Friday, 7<sup>th</sup> October 2022
Virtual Forum

sanofi



# **SUMMARY**



Welcome letter	4
Agenda	5
SPEAKER BIOGRAPHIES	
Professor Hartleb	6
Professor Fricker	7
Professor Mao	8
Donna R. Cryer	9
IMPORTANT INFORMATION	
Useful information on SpotMe platform access	.10

# **WELCOME LETTER**



It gives us great pleasure to welcome you to the final webinar of the **3rd Global Liver Health Forum!** Following the success of the 2nd Global Liver Health Forum, we aim to continue to raise awareness of the key factors influencing disease management across the liver health landscape. We hope this programme will accommodate your busy schedules and ensure you get the most recent information to help to optimise your patient management.

During this second session of the webinar series, we will explore the common cardiometabolic risk factors associated with metabolic associated fatty liver disease (MAFLD), consider the interplay between liver diseases and COVID-19, broaden our understanding of the molecular mechanisms of essential phospholipid (EPL), and explore the impact of drug-induced liver injury (DILI) on patients and clinical outcomes with a focus on early disease recognition. We will also hear brand new insights from the Global Liver Institute (GLI).

While we hope to return to face-to-face meetings in the future, adapting to a hybrid working environment continues to allow for a broader range of perspectives from participants across the globe. Throughout the meeting, there will be ample opportunity to engage with the faculty and we encourage you to ask questions in the Q&A sessions and panel discussion.

This event presents an exciting opportunity to exchange with and learn from world-renowned scientific experts, who will provide insights in diagnoses and risks associated with liver diseases and their management. In bringing together this international network of healthcare professionals, the Global Liver Health Forum can facilitate a powerful information exchange that will elevate the quality of patient management. We hope that you and your peers from all over the world will enjoy this engaging and insightful meeting.


We would like to express our sincere gratitude to the people who made this meeting possible. We extend a special thanks to our faculty, who have dedicated their time to sharing their knowledge and passion with us all. We are sure the second webinar of the 3rd Global Liver Health Forum will make for a highly informative and successful meeting.

Yours sincerely,

#### **Branko Popovic**

Global Medical Lead for Digestive Wellness, Sanofi Consumer Healthcare





accommodate for a global audience and ensure all interested viewers can attend.


#### Sessions 1&2 (morning and afternoon sessions) – Friday, 7th October 2022

TIME CET (UTC+2) Morning Session	TIME CEST (UTC+2) Afternoon Session	TOPICS	SPEAKER	
10:00-10:10	16:00-16:10	Welcome and introduction	Sanofi, Professor Hartleb (Chair, PL), Andrea Cole (moderator, UK)	
Session 1				
10:10-10:25	16:10-16:25	Cardiovascular and metabolic risks of MAFLD: important considerations for clinical practice	Professor Hartleb (PL)	
10:25-10:40	16:25-16:40	The potential molecular mechanism of EPL: insights from EASL 2022	Professor Fricker (DE)	
10:40-10:50	16:40-16:50	Q&A		
10:50-11:00	16:50-17:00	Break		
Session 2				
11:00-11:15	17:00-17:15	Diagnosis and treatment of drug-induced liver injury: guidelines and practice	Professor Mao (CN)	
11:15-11:25	17:15-17:25	Defying the trends: leveraging liver health to improve patient and public health	Donna R. Cryer, JD (US)	
11:25-11:45	17:25-17:45	Q&A and panel discussion		
11:45-11:50	17:45-17:50	Summary and closing remarks		









## **Professor Hartleb**

Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland

Professor Hartleb, MD, obtained his medical degree from the Medical University of Silesia in Katowice, Poland, where he pursued a specialisation in internal medicine and gastroenterology. In 1989, he was the recipient of a Fellowship of the French Ministry of Foreign Affairs and Laboratoires Fournier, which allowed him to spend 2 years working in the Splanchnic Hemodynamic Laboratory at Beaujon Hospital in Clichy, Paris, France. In 2005, he was appointed Professor of Medicine.

Professor Hartleb currently serves as the Head of the Department of Gastroenterology and Hepatology at the Medical University of Silesia in Katowice. He is also the Head of the Scientific Committee of the School of Medicine in the same institution. Since 2014, he has been the President of the Hepatology Section of the Polish Gastroenterology Society, where he also holds the post of the Vice President. He is the Editor-in-Chief of the national scientific journal Gastroenterologia Praktyczna (Practical Gastroenterology).

# Cardiovascular and metabolic risks of MAFLD: important considerations for clinical practice

#### **Presentation overview:**

- The paradigm shift from non-alcoholic fatty liver disease (NAFLD) to MAFLD and its implications for clinical practice
- Discussion of the bidirectional association between cardiometabolic disorders (such as cardiovascular disease and type 2 diabetes) and NAFLD
- Summary of the hepatic effects of pharmacological treatment options for patients with NAFLD and cardiometabolic disorders
- EPL summary of data in stabilisation of lipids profile in patients with MAFLD





Institute of Pharmacy and Molecular Biotechnology, Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany

Professor Fricker, MD, is a Professor at the Institute of Pharmacy and Molecular Biotechnology in the Faculty of Biosciences, University of Heidelberg, Germany. In 1995, Professor Fricker was appointed Professor at the University of Heidelberg, following which in 2002, he became Chair for Pharmaceutical Technology. In addition to his university affiliation, Professor Fricker is Head of the Technology Transfer Centre Biopharmacy and Analytics in Heidelberg, a service centre for the pharmaceuticals industry. In 2016, he was initiator of the university spin-off company HEIDELTEC GmbH, dealing with oral peptide drug delivery.

His main research interests are the permeation of drugs across barrier tissues with particular emphasis on the intestine and blood-brain barrier as well as the development of drugtargeting systems by colloidal drug carriers.

### The potential molecular mechanism of EPL: insights from EASL 2022


#### **Presentation overview:**

- Overview of the first study of EPL in steatotically changed HepaRG cell lines and potential insights into the mechanism of action of EPL
- Summary of key findings presented by Wupperfeld et al. ILC 2022
  - Overview of methodology
  - Key results, including effects on cytokines and lipid metabolising enzymes









## **Professor Mao**

Research Centre of Shanghai Fatty Liver Disease, Gastroenterology Department, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Professor Mao is Director of the Research Centre of Shanghai Fatty Liver Disease, and Chief Physician and Professor of the Gastroenterology Department at Renji Hospital, Shanghai Jiao Tong University School of Medicine, China.


Professor Mao is currently a member of a number of international organisations, including the DILI Working Group of Council for International Organizations of Medical Sciences (CIOMS), as well as President of the study group for DILI at the Chinese Society of Hepatology, Chinese Medical Association, and Vice President at the Chinese Association for the Study of Clinical Toxicology.

As principal investigator, Professor Mao has conducted more than 200 clinical trials in the field of gastroenterology and liver disease in China. He is also the leading principal investigator of National Eleven-Five and Twelve-Five Projects for building up a clinical and translational research platform for liver disease in China. He has published more than 200 papers as first or corresponding author, in journals including *Gastroenterology, Hepatology* or *Liver International*, among many others.

## Diagnosis and treatment of drug-induced liver injury: guidelines and practice

#### **Presentation overview:**

- Overview of the leading causes of DILI, its diagnosis and treatment; treatment and management to be discussed in the context of the 2021 APASL guidelines and Chinese guidelines which are due to be updated in 2022
- The difference between DILI in the East and the West, including herbal and dietary supplements induced liver injury and treatment options
- An overview of liver injuries, COVID-19 and the potential connections with DILI
- Place and role of hepatoprotective treatment options in the pharmacotherapy of DILI, including overview of clinical data of EPL as adjunctive treatment in DILI indications





Global Liver Institute, Washington, DC, USA

Donna R. Cryer, Mrs. Cryer is Founder and CEO of GLI, the leading patient advocacy organisation in liver health, convening more than 200 organisations across 70 countries. A graduate of Harvard and Georgetown Law, she serves on several boards, including Sibley Memorial Hospital/Johns Hopkins Medicine and the Council of Medical Speciality Societies. She is widely recognised as an expert on the topics of patient engagement in research, digital health, and high-value equitable care, advancing the voice of patients and in equitable healthcare has been recognised globally.

Through the GLI, Mrs Cryer has been instrumental in raising more than US\$10 million in funds for liver health initiatives and convening with more than 200 organisations within the liver health landscape, facilitating collaborative, multi-stakeholder agenda setting to pave the way for new innovations and adoption of best practices to improve patient outcomes.

## Defying the trends: leveraging liver health to improve patient and public health


#### **Presentation overview:**

- Overview of the issue of rising trends in comorbidities that have led to an increase in liver disease
- How the GLI creates collaborative processes to respond to these liver health needs, including through International #NASHDay, GLI's NASH Council, GLI Live, as well as the Beyond the Biopsy programme
- How public awareness can be improved through education, dissemination, and advocacy of the liver health landscape











All webinars will be broadcasted on Sanofi's partner platform, **SpotMe**.

**SpotMe** is a digital platform which allows a better engagement between speakers and the audience. Below are some technical recommendations to ensure you will get the best experience during the event.

#### **During the webinar:**

Attendees will have access to the agenda, resources, question and answer polls, speaker CVs, presentations, post-event book, as well as infographics and lecture summaries of the sessions. The audience will also have the chance to socialise and network with other attendees also on the **SpotMe** platform. The platform will remain open for 1 month after the webinar, so that attendees can continue to access the materials.

Live translations of the webinars will be available in Mandarin, Czech, Polish, Romanian, Russian, and Vietnamese.

In addition, the **SpotMe** platform will provide pre- and post-event surveys, polls, and patient case scenarios for attendees to complete.

#### Joining a live stream webinar on SpotMe

Browser requirements:

- Only desktop Chrome-based browsers are supported (e.g., Google Chrome, Microsoft Edge (79+), Opera or Brave). The 64-bit versions of these browsers are recommended.
- SpotMe's domains and services are required access through the network firewall **Network recommendations:** 
  - At least 10 mbps upload/download speed (internet speed can be tested using fast. com or any other suitable website)
  - Wired internet connection







sanofi

MAT-GLB-2203931-v-1.0
Date of approval: October 2022